NASDAQ:PHAR Pharming Group - PHAR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pharming Group Please log in to your account or sign up in order to add this asset to your watchlist. $10.71 -0.56 (-4.97%) (As of 03/24/2023 11:50 AM ET) Add Compare Share Share Today's Range$10.03▼$11.1150-Day Range$10.24▼$14.7852-Week Range$6.10▼$15.00Volume14,268 shsAverage Volume6,858 shsMarket Capitalization$703.00 millionP/E Ratio56.37Dividend YieldN/APrice Target$37.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Pharming Group MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside254.1% Upside$37.00 Price TargetShort InterestHealthy0.00% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.36Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.22 out of 5 starsMedical Sector329th out of 989 stocksPharmaceutical Preparations Industry145th out of 480 stocks 3.5 Analyst's Opinion Consensus RatingPharming Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.00, Pharming Group has a forecasted upside of 254.1% from its current price of $10.45.Amount of Analyst CoveragePharming Group has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.00% of the outstanding shares of Pharming Group have been sold short.Short Interest Ratio / Days to CoverPharming Group has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pharming Group has recently decreased by 33.33%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPharming Group does not currently pay a dividend.Dividend GrowthPharming Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHAR. Previous Next 2.0 News and Social Media Coverage News SentimentPharming Group has a news sentiment score of -0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Pharming Group this week, compared to 1 article on an average week.Search Interest36 people have searched for PHAR on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days.MarketBeat Follows3 people have added Pharming Group to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pharming Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.07% of the stock of Pharming Group is held by insiders.Percentage Held by InstitutionsOnly 0.04% of the stock of Pharming Group is held by institutions. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharming Group is 55.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 123.11.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharming Group is 55.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 96.90.Price to Book Value per Share RatioPharming Group has a P/B Ratio of 3.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Pharming Group (NASDAQ:PHAR) StockPharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.Read More Receive PHAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. Email Address PHAR Stock News HeadlinesMarch 18, 2023 | finance.yahoo.comPharming Group Full Year 2022 Earnings: EPS: US$0.021 (vs US$0.025 in FY 2021)March 17, 2023 | americanbankingnews.comPharming Group (NASDAQ:PHAR) Shares Gap Down to $12.65March 24, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 16, 2023 | marketwatch.com2023 Lactoferrin and Lactoperoxidase Market Size Forecast 2029: Global Leaders' Sales and Profit Analysis for Business GrowthMarch 15, 2023 | marketwatch.comHereditary Angioedema Therapeutic Market Application, Product, Sales and Forecast 2023-2028March 14, 2023 | finance.yahoo.comWhy Earnings Season Could Be Great for Pharming Group (PHAR)March 13, 2023 | marketwatch.comPharming Expects to Have Access to $26 Mln It Has on Deposit at SVB USMarch 13, 2023 | finance.yahoo.comPharming Group announces that it expects to have full access today to its cash on deposit at Silicon Valley Bank Limited in light of UK Government announcementMarch 24, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 12, 2023 | finanznachrichten.dePharming Group N.V.: Pharming Group issues statement regarding the events surrounding Silicon Valley BankMarch 12, 2023 | finance.yahoo.comPharming Group issues statement regarding the events surrounding Silicon Valley BankMarch 12, 2023 | finance.yahoo.comDutch biotech Pharming says it held $45 mln in collapsed SVBFebruary 17, 2023 | marketwatch.comIschemia Reperfusion Injury Therapeutics Market Insights-Industry changing aspects, New Technologies and Forecast to 2028February 16, 2023 | msn.comWhy Boston Beer Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionFebruary 16, 2023 | finanznachrichten.dePharming Group N.V.: Pharming provides update on EMA regulatory review of leniolisib for APDS in EuropeFebruary 16, 2023 | finance.yahoo.comPharming provides update on EMA regulatory review of leniolisib for APDS in EuropeFebruary 13, 2023 | marketwatch.comRecombinant Proteins for Clinical Use Market Will Touch New Level in Upcoming YearJanuary 19, 2023 | marketwatch.comHereditary Angioedema Treatment Market 2023 : Company Profile Analysis, Industry Segmentation, Opportunity Assessment and Forecast by 2028December 15, 2022 | markets.businessinsider.comPharming Reports Positive Interim Data From Study Of Leniolisib In Rare Primary ImmunodeficiencyDecember 7, 2022 | seekingalpha.comPharming reports publishing of phase 3 data of rare immunodeficiency disorder drugDecember 7, 2022 | finanznachrichten.dePharming Group NV: Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's BloodDecember 7, 2022 | markets.businessinsider.comPharming : Positive Data From Phase 3 Study Of Leniolisib In Rare Primary Immunodeficiency PublishedDecember 7, 2022 | marketwatch.comPharming Group's Leniolisib Phase 3 Study Shows Positive DataDecember 1, 2022 | finance.yahoo.comHas Pharming Group (PHAR) Outpaced Other Medical Stocks This Year?November 24, 2022 | finanznachrichten.dePharming Group N.V.: Pharming Group announces presentation of new leniolisib data at 2022 ASH Annual MeetingNovember 3, 2022 | finanznachrichten.dePharming Group N.V.: Pharming to present at Stifel Healthcare ConferenceNovember 3, 2022 | finance.yahoo.comPharming to present at Jefferies Healthcare ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PHAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. Email Address PHAR Company Calendar Today3/24/2023Next Earnings (Estimated)5/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PHAR CUSIPN/A CIK1828316 Webwww.pharming.com Phone31-71-524-7400FaxN/AEmployees262Year FoundedN/APrice Target and Rating Average Stock Price Forecast$37.00 High Stock Price Forecast$37.00 Low Stock Price Forecast$37.00 Forecasted Upside/Downside+254.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.19 Trailing P/E Ratio55.00 Forward P/E RatioN/A P/E GrowthN/ANet Income$13.67 million Net Margins6.65% Pretax Margin7.29% Return on Equity1.08% Return on Assets0.54% Debt Debt-to-Equity Ratio0.64 Current Ratio4.65 Quick Ratio3.94 Sales & Book Value Annual Sales$205.62 million Price / Sales3.34 Cash Flow$0.23 per share Price / Cash Flow44.76 Book Value$3.12 per share Price / Book3.35Miscellaneous Outstanding Shares65,640,000Free Float64,276,000Market Cap$685.94 million OptionableNot Optionable Beta0.26 Key ExecutivesDr. Sijmen de Vries M.B.A. (Age 63)M.D., MBA, Pres, CEO & Exec. Director Comp: $1.2MDr. Bruno M. L. Giannetti (Age 70)Consultant Mr. Jeroen Wakkerman (Age 53)Chief Financial Officer Ms. Mireille Sanders M.Sc. (Age 54)Chief Operations Officer Susanne EmbletonInvestor Relations Mang.Mr. Ruud Van Outersterp (Age 58)Chief Ethics & Compliance Officer Mr. Anurag Relan (Age 50)Chief Medical Officer Mr. Stephen Toor (Age 51)Chief Commercial Officer & GM of Americas More ExecutivesKey CompetitorsViking TherapeuticsNASDAQ:VKTXCymaBay TherapeuticsNASDAQ:CBAYSeres TherapeuticsNASDAQ:MCRBInnovivaNASDAQ:INVAKiniksa PharmaceuticalsNASDAQ:KNSAView All CompetitorsInstitutional OwnershipCowen Prime Advisors LLCBought 4,910 shares on 2/1/2023Ownership: 0.033%View All Institutional Transactions PHAR Stock - Frequently Asked Questions Should I buy or sell Pharming Group stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pharming Group in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PHAR shares. View PHAR analyst ratings or view top-rated stocks. What is Pharming Group's stock price forecast for 2023? 1 equities research analysts have issued twelve-month price targets for Pharming Group's stock. Their PHAR share price forecasts range from $37.00 to $37.00. On average, they predict the company's stock price to reach $37.00 in the next twelve months. This suggests a possible upside of 254.1% from the stock's current price. View analysts price targets for PHAR or view top-rated stocks among Wall Street analysts. How have PHAR shares performed in 2023? Pharming Group's stock was trading at $11.03 at the beginning of the year. Since then, PHAR stock has decreased by 5.3% and is now trading at $10.45. View the best growth stocks for 2023 here. Are investors shorting Pharming Group? Pharming Group saw a drop in short interest in February. As of February 28th, there was short interest totaling 2,000 shares, a drop of 33.3% from the February 13th total of 3,000 shares. Based on an average daily volume of 4,300 shares, the days-to-cover ratio is presently 0.5 days. View Pharming Group's Short Interest. When is Pharming Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our PHAR earnings forecast. What is Pharming Group's stock symbol? Pharming Group trades on the NASDAQ under the ticker symbol "PHAR." Who are Pharming Group's major shareholders? Pharming Group's stock is owned by a number of retail and institutional investors. Top institutional investors include Cowen Prime Advisors LLC (0.03%). How do I buy shares of Pharming Group? Shares of PHAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pharming Group's stock price today? One share of PHAR stock can currently be purchased for approximately $10.45. How much money does Pharming Group make? Pharming Group (NASDAQ:PHAR) has a market capitalization of $685.94 million and generates $205.62 million in revenue each year. The company earns $13.67 million in net income (profit) each year or $0.19 on an earnings per share basis. How many employees does Pharming Group have? The company employs 262 workers across the globe. How can I contact Pharming Group? Pharming Group's mailing address is DARWINWEG 24, LEIDEN P7, 2333 CR. The official website for the company is www.pharming.com. The company can be reached via phone at 31-71-524-7400 or via email at investor@pharming.com. This page (NASDAQ:PHAR) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.